Literature DB >> 12738145

Survival and prognostic factors in patients with ovarian cancer.

Solveig Tingulstad1, Finn Egil Skjeldestad, Tore B Halvorsen, Bjørn Hagen.   

Abstract

OBJECTIVE: To assess incidence during a 10-year study period and to identify and discuss clinical relevance for prognostic factors of survival within a cohort of Norwegian ovarian cancer patients.
METHODS: Incidence and prognostic factors of survival within a population-based cohort of ovarian cancer patients from one health region in Norway were examined over the 10-year period 1987 through 1996. A total of 571 histologically verified cases of primary ovarian cancer originally registered either in the Cancer Registry of Norway or in the hospital's discharge registers were included in the study. Pearson chi(2) test was used in univariate analyses of cofactors by 5-year survival, and Kaplan-Meier survival curves were computed and tested statistically by the log rank test. A multivariable proportional hazard model (Cox) was applied to assess the prognostic significance of the different covariates.
RESULTS: The incidence and crude 5-year survival remained stable over the 10-year study period. The standardized incidence rate for the time periods 1987-1991 and 1992-1996 was 11.9/100,000 and 12.5/100,000, respectively. The crude 5-year survival rate for the cohort was 39%, whereas median survival was 32 months. Cox multivariable regression analysis showed that the only independent significant prognostic factors were International Federation of Gynecology and Obstetrics stage (P <.001), size of residual tumor at the end of primary surgery (P <.001), and age at diagnosis (P <.01). Variables such as time period, histologic type and grade, treating hospital, comorbidity, or CA 125 were insignificant in predicting 5-year survival.
CONCLUSION: The results underline the importance of improved surgical management of ovarian cancer, as residual tumor is the only prognostic factor achievable.

Entities:  

Mesh:

Year:  2003        PMID: 12738145     DOI: 10.1016/s0029-7844(03)00123-6

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  38 in total

1.  Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer.

Authors:  Xiaojian Ni; Jingjing Ma; Yingchun Zhao; Ying Wang; Shui Wang
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.

Authors:  Jeong Won Lee; Arthur Cho; Jae-Hoon Lee; Mijin Yun; Jong Doo Lee; Young Tae Kim; Won Jun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-23       Impact factor: 9.236

3.  A polymorphism at miRNA-122-binding site in the IL-1α 3'UTR is associated with risk of epithelial ovarian cancer.

Authors:  Zhu Zhang; Bin Zhou; Qianqian Gao; Yuke Wu; Kui Zhang; Yan Pu; Yaping Song; Lin Zhang; Mingrong Xi
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

4.  AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma.

Authors:  Jiangdong Xiang; Lina Zhou; Shuangdi Li; Xiaowei Xi; Jiarong Zhang; Yanqiu Wang; Yixia Yang; Xuelian Liu; Xiaoping Wan
Journal:  Oncol Lett       Date:  2012-01-16       Impact factor: 2.967

5.  Prognostic value of IL-27 polymorphisms and the susceptibility to epithelial ovarian cancer in a Chinese population.

Authors:  Zhu Zhang; Bin Zhou; Yuke Wu; Qianqian Gao; Kui Zhang; Yaping Song; Lin Zhang; Mingrong Xi
Journal:  Immunogenetics       Date:  2013-12-19       Impact factor: 2.846

6.  Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer.

Authors:  Hyun Hoon Chung; Maria Lee; Hee-Seung Kim; Jae-Weon Kim; Noh-Hyun Park; Yong Sang Song; Gi Jeong Cheon
Journal:  Eur Radiol       Date:  2017-06-07       Impact factor: 5.315

7.  Impact of cardiovascular comorbidity on ovarian cancer mortality.

Authors:  Eileen H Shinn; Daniel J Lenihan; Diana L Urbauer; Karen M Basen-Engquist; Alan Valentine; Laura Palmero; Myrshia L Woods; Pooja Patel; Alpa M Nick; Mian M K Shahzad; Rebecca L Stone; Antoinette Golden; Emma Atkinson; Susan K Lutgendorf; Anil K Sood
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

Review 8.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

9.  Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years.

Authors:  Zeinab Hamidou; Sylvain Causeret; Tienhan S Dabakuyo; Julie Gentil; Laurent Arnould; Patrick Roignot; Thierry Altwegg; Marie-Laure Poillot; Franck Bonnetain; Patrick Arveux
Journal:  BMC Cancer       Date:  2010-11-10       Impact factor: 4.430

10.  The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago.

Authors:  Charlotte E Joslin; Katherine C Brewer; Faith G Davis; Kent Hoskins; Caryn E Peterson; Heather A Pauls
Journal:  Gynecol Oncol       Date:  2014-08-28       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.